BiomEdit
Overview
BiomEdit is an innovative company focused on developing microbiome-derived products to address unmet needs in animal health. Founded in 2022, BiomEdit operates from Fishers, Indiana and was established as a collaborative effort between Elanco Animal Health and Ginkgo Bioworks. The company has successfully raised $18.4 million through its Series B funding round. BiomEdit focuses on leveraging the animal microbiome and synthetic biology to create solutions for disease prevention and animal health promotion.
Recent Developments
-
July 2025: BiomEdit announced that its BE-101 product, aimed at combating necrotic enteritis in poultry, is advancing to the final phase of the USDA's conditional licensure and is slated for commercialization in 2026. They secured $18.4 million in Series B funding, with Anterra Capital leading the investment round. The company also added key executives - Kristin Bloink as Vice President of Development and Andrew Carlson as Chief Commercial Officer.
-
February 2024: BiomEdit's CEO Aaron Schacht was honored as Visionary CEO by S&P Global Animal Health Awards. The company was also recognized for its innovative approaches in addressing animal health challenges.
-
September 2023: Successfully secured grants for various research programs. These grants include targeting Avian Influenza with a novel biologic solution and a significant NIH award for research into human therapeutic applications based on BiomEdit's technologies.
-
July 2023: BiomEdit announced that it has completed pivotal efficacy trials for its BE-101, showing the potential to reduce mortality and increase performance in poultry significantly. The product has also received all necessary regulatory approvals for laboratory safety studies.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2022 |
| Headquarters | Fishers, Indiana, USA |
| Founders | Elanco Animal Health and Ginkgo Bioworks |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Anterra Capital, Nutreco, AgriZeroNZ, Elevate Ventures, Betagro Ventures |
| Industry | Animal Health, Biotechnology |
| Number of Employees | Approximately 50 |
Early History
BiomEdit was founded shortly after Elanco Animal Health spun off its microbiome division, joining forces with Ginkgo Bioworks, a leader in cell programming. The company was officially launched in April 2022 with an initial focus on leveraging its proprietary microbiome platform to address challenges in animal health. Early funding came through a Series A round, raising $40 million from investors like Viking Global Investors and Anterra Capital, providing the capital needed to rapidly develop their unique probiotics and bioactive products.
Company Profile and Achievements
BiomEdit's core business model involves the development of microbiome-derived biotech solutions intended to improve animal health and productivity. One of its cornerstone products is BE-101, a probiotic vectored antibody designed to combat necrotic enteritis in poultry, a disease causing massive economic losses in the poultry industry. The product has successfully passed several critical stages in the USDA's regulatory process, setting a new precedent for biologically engineered animal health solutions.
Key milestones include:
- Engineering probiotics that contain antibodies against toxins produced by harmful bacteria.
- Securing $1.7 million in research grants to explore methane reduction in cattle.
- Building strategic partnerships to enhance product development and market penetration.
- Achieving recognition for thought leadership in animal health innovation.
Current Operations and Market Position
Currently, BiomEdit is leading the charge in developing microbiome-based products that significantly reduce the reliance on antibiotics in animal agriculture. With its pioneering BE-101 product expected to hit the market by 2026, the company is poised to revolutionize how poultry health is managed. The company's strategic partnerships and funding acquisition have positioned it well to penetrate the U.S. market rapidly, and expansion plans are underway for international markets such as Brazil, due to its large and evolving poultry industry.
Conclusion
BiomEdit stands at the forefront of the animal health industry with its innovative application of microbiome science and synthetic biology. By pioneering products like BE-101, BiomEdit is not only poised to redefine poultry health management but also plans to expand into additional livestock areas. Given its robust pipeline and strategic advancements, BiomEdit is well-positioned to make significant impacts in animal agriculture, enhancing sustainability and productivity across global markets.